Key result
DCB PCI linked to ~46% lower 2-year NACE risk vs DES in acute MI.
Why the study?
Data on drug-coated balloon treatment in acute myocardial infarction were limited.
Does a drug-coated balloon-based PCI strategy reduce net adverse cardiovascular events in patients with de novo acute myocardial infarction compared to conventional DES-only PCI?
Cohort (n=3,169)
Yes
Does a drug-coated balloon-based PCI strategy reduce net adverse cardiovascular events in patients with de novo acute myocardial infarction compared to conventional DES-only PCI?
Hazard Ratio: 0.54 (95% CI 0.33–0.88)
Absolute Event Rate: 6.2% vs 10.8%
p-value: p=0.014
In patients with de novo acute myocardial infarction, a drug-coated balloon-based PCI strategy significantly reduced the 2-year risk of net adverse cardiovascular events, target vessel revascularization, and major bleeding compared to conventional drug-eluting stent implantation.
DCB-based PCI was associated with lower NACE in de novo AMI; hypothesis-generating and requires randomized confirmation.
PURPOSE: Data on drug-coated balloon (DCB) treatment in acute myocardial infarction (AMI) are limited. We aimed to assess the efficacy and safety of DCB revascularization in percutaneous coronary intervention (PCI) in patients with de novo AMI. MATERIALS AND METHODS: Three hundred twenty-nine patients with de novo AMI who were successfully treated with DCB-based PCI were retrospectively enrolled. Patients treated with DCB-based PCI were compared to propensity score-matched patients who underwent conventional PCI with second-generation drug-eluting stent (DES), using data from a DES registry. Both groups were followed over 2 years to assess net adverse cardiovascular events (NACE). RESULTS: =0.027] were significantly lower in the DCB-based group compared to the DES-only group after 2 years of follow-up. These results remained consistent after adjusting for baseline differences using multivariable regression, propensity score matching, and inverse probability of treatment weighting. In a multivariable model, DCB-based PCI was independently associated with reduced risk of 2-year NACE, target vessel revascularization, and major bleeding. CONCLUSION: In patients with de novo AMI, DCB-based PCI showed more favorable clinical outcomes after 2 years of follow-up compared to conventional DES-only PCI. DCB-based PCI may serve as a safe and effective alternative to DES-only PCI in carefully selected patients with satisfactory pre-dilation results (Impact of Drug-Coated Balloon Treatment in De Novo Coronary Lesion; NCT04619277).
No takes yet. Share an insight, caveat, or question.
Her et al. (2025) conducted a cohort in de novo acute myocardial infarction (n=3,169). Drug-coated balloon-based percutaneous coronary intervention vs. Conventional percutaneous coronary intervention with second-generation drug-eluting stent was evaluated on Net adverse cardiovascular events (NACE) (HR 0.54, 95% CI 0.33-0.88, p=0.014). Drug-coated balloon-based percutaneous coronary intervention significantly reduced the 2-year risk of net adverse cardiovascular events by 46% (HR 0.54) compared to drug-eluting stents in patients with de novo acute myocardial infarction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: